胃肠间质瘤临床诊治现状与进展

中国临床药理学与治疗学 ›› 2017, Vol. 22 ›› Issue (11): 1315-1320.

• 综述与讲座 • 上一篇

胃肠间质瘤临床诊治现状与进展

何苗¹，范晶²，王子卫³，赵和照¹

¹重庆市肿瘤研究所胃肠外科，重庆大学附属肿瘤医院，重庆 400030； ²重庆医科大学附属第一医院急诊科，重庆 400016；³重庆医科大学附属第一医院普通外科，重庆 400016

收稿日期:2017-04-06 修回日期:2017-06-18 出版日期:2017-11-26 发布日期:2017-12-11
通讯作者: 赵和照，男，本科，副主任医师,研究方向：胃肠道肿瘤基础与临床。 Tel：13608369620 E-mail：zhzalee@163.com
作者简介:何苗，男，博士，主治医师,研究方向：胃肠外科基础与临床。 Tel：13996123692 E-mail：hemiao7777777@163.com

Progress of diagnosis and therapy on gastrointestinal stromal tumors

HE Miao ¹, FAN Jing ², WANG Ziwei³, ZHAO Hezhao ¹

¹Department of Gastrointestinal Surgery, Chongqing Cancer Institute,ChongQing University Cancer Hospital, Chongqing 400030, China; ²Department of Emergency,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China; ³ Department of General Surgery,the first Affiliated Hospital of Chongqing Medical University, Chongqing 400016,China

Received:2017-04-06 Revised:2017-06-18 Online:2017-11-26 Published:2017-12-11

摘要/Abstract

摘要：

胃肠间质瘤（gastrointestinal stromal tumors,GISTs）是临床常见的间叶细胞来源肿瘤，目前对其发病机制的理解已明显促进其临床诊治进展，甚至该肿瘤的诊治已成为肿瘤多学科联合诊疗领域的典范。本文综述GIST临床诊治现状与进展，包括病理诊断、手术治疗与药物治疗方面，以期为临床医师提供参考。

关键词: 胃肠间质瘤, 诊断, 治疗, 进展, 酪氨酸激酶抑制剂

Abstract:

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors originating in the gastrointestinal tract. The understanding of GIST's pathogenesis improves the clinical diagnosis and treatment of this disease. And the diagnosis and treatment of GIST becomes the model of tumor multidisciplinary treatment. This article summarizes the progress of diagnosis and treatment of GIST, including the pathology, surgery and drug therapy. We hope this overview can help clinical doctors to treat GIST patients better.

Key words: GIST, diagnosis, therapy, progress, TKI

中图分类号:

R735

何苗，范晶，王子卫，赵和照. 胃肠间质瘤临床诊治现状与进展[J]. 中国临床药理学与治疗学, 2017, 22(11): 1315-1320.

HE Miao, FAN Jing, WANG Ziwei, ZHAO Hezhao. Progress of diagnosis and therapy on gastrointestinal stromal tumors[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(11): 1315-1320.

参考文献

［1］Yan L, Zou L, Zhao W, et al. Clinicopathological significance of c-KIT mutation in gastrointestinal stromal tumors: a systematic review and meta-analysis［J］. Sci Rep, 2015, 5: 13718.
［2］Lin JX, Chen QF, Zheng CH, et al. Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up［J］. J Cancer Res Clin Oncol, 2017, 143(4): 727-734.
［3］Ricci R, Saragoni L. Everything you always wanted to know about GIST (but were afraid to ask) an update on GIST pathology［J］. Pathologica, 2016, 108(3): 90-103.
［4］Oudijk L,Gaal J,Korpershoek E,et al.SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors［J］.Mod Pathol,2013,26(3):456-463.
［5］Yanagimoto Y, Takahashi T, Muguruma K, et al. Re-appraisal of risk classifications for primary gastrointestinal stromal tumors (GISTs) after complete resection: indications for adjuvant therapy［J］. Gastric Cancer, 2015, 18(2): 426-433.
［6］Ignee A, Jenssen C, Hocke M, et al. Contrast-enhanced(endoscopic) ultrasound and endoscopic ultrasound elastography in gastrointestinal stromal tumors［J］. Endosc Ultrasound, 2017, 6(1): 55-60.
［7］Nakano A, Nakamura M, Watanabe O, et al. Endoscopic characteristics, risk grade, and prognostic prediction in gastrointestinal stromal tumors of the small bowel［J］. Digestion, 2017, 95(2): 122-131.
［8］An HJ, Ryu MH, Ryoo BY, et al. The effects of surgical cytoreduction prior to imatinib therapy on the prognosis of patients with advanced GIST［J］. Ann Surg Oncol, 2013, 20(13): 4212-4218.
［9］Milone M, Elmore U, Musella M, et al. Safety and efficacy of laparoscopic wedge gastrectomy for large gastrointestinal stromal tumors［J］. Eur J Surg Oncol, 2017, 43(4): 796-800.
［10］Zhi X, Jiang B, Yu J, et al. Prognostic role of microscopically positive margins for primary gastrointestinal stromal tumors: a systematic review and meta-analysis［J］. Sci Rep, 2016, 6: 21541
［11］Kubo N, Takeuchi N. Gastrointestinal stromal tumor of the stomach with axillary lymph node metastasis: a case report［J］. World J Gastroenterol, 2017, 23(9): 1720-1724.
［12］Pelletier JS, Gill RS, Gazala S, et al. A systematic review and meta-analysis of open vs. laparoscopic resection of gastric gastrointestinal stromal tumors［J］. J Clin Med Res, 2015, 7(5): 289-296.
［13］Joensuu H, Reichardt P, Eriksson M, et al. Gastrointestinal stromal tumor: a method for optimizing the timing of CT scans in the follow-up of cancer patients［J］. Radiology, 2014, 271(1): 96-103.
［14］Du CY, Zhou Y, Song C, et al. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China［J］. Eur J Cancer, 2014, 50(10): 1772-1778.
［15］Park SJ, Ryu MH, Ryoo BY, et al. The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses［J］. Ann Surg Oncol, 2014, 21(13): 4211-4217.
［16］Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial［J］. Lancet, 2009, 373(9669): 1097-1104.
［17］Li J, Gong JF, Wu AW, et al. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor ［J］. Eur J Surg Oncol, 2011, 37(4): 319-324.
［18］Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial［J］. JAMA, 2012, 307(12): 1265-1272.
［19］Fu Y, Hao H, Guo L, et al. Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor［J］. Oncotarget, 2017, 8(6): 10136-10144.
［20］Rossi S, Congedo T, Ricci R, et al. Is surgery mandatory in locally advanced gastrointestinal stromal tumors after imatinib? A case report and literature review［J］. J gastrointest Oncol, 2017, 8(1): E4-9.
［21］Le Cesne A, Ray-Coquard I, Bui BN, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial［J］. Lancet Oncol, 2010, 11(10): 942-949.
［22］Tirumani SH, Baheti AD, Tirumani H, et al. Update on gastrointestinal stromal tumors for radiologists［J］. Korean J Radiol, 2017, 18(1): 84-93.
［23］Sym SJ, Ryu MH, Lee JL, et al. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs)［J］. J Surg Oncol, 2008, 98(1): 27-33.
［24］Yoo C, Ryu MH, Ryoo BY, et al. Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800mg/day in patients with advanced gastrointestinal stromal tumors［J］. Invest New Drugs, 2013, 31(5): 1367-1374.
［25］Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial［J］. Lancet, 2006, 368(9544): 1329-1338.
［26］Li J, Gao J, Hong J, Shen L. Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors［J］. Future Oncol, 2012, 8(5): 617-624.
［27］Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial［J］. Lancet, 2013, 381(9863): 295-302.
［28］Kang YK, Ryu MH, Yoo C, et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial［J］. Lancet Oncol, 2013, 14(12): 1175-1182.
［29］Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors［J］. J Clin oncol, 2009,27(19):3141-3147.
［30］Hompland I, Bruland YS, Ubhayasekhera K, et al. Clinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour［J］. Clin Sarcoma Res, 2016,6:21.
［31］Xu H,Ma L,Xu W,et al.A Chinese multi-center study on the significance of monitoring imatinib plasma concentration in patients with gastrointestinal stromal tumor before and after administration［J］.Zhonghua Wei Chang Wai Ke Za Zhi,2016,19(11):1271-1276.
［32］Yoo C, Ryu MH, Kang BW,et al. Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors:impact of gastrointestinal resection on exposure to imatinib［J］. J Clin Oncol, 2010, 28(9):1554-1559.

[1]	何李华, 朱秀之, 江一舟. 三阴性乳腺癌免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 842-853.
[2]	张胡云龙, 朱秀之, 金希, 邵志敏. 腔面型乳腺癌内分泌治疗耐药的机制与治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 854-865.
[3]	付晓玉, 孔德光, 李娟娟. 三阳性乳腺癌的治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 866-875.
[4]	罗师萍, 张捷, 俞育帅, 宋传贵. HER2阳性乳腺癌的靶向治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 876-886.
[5]	向奕玫, 张宁宁, 黄雨昕, 曾晓华. HER2阳性乳腺癌疗效相关生物标志物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 887-897.
[6]	侯琼, 刘飞, 陈传荣. 免疫治疗联合抗血管生成药物+化疗在驱动基因阴性晚期非小细胞肺癌中的应用[J]. 中国临床药理学与治疗学, 2023, 28(7): 775-779.
[7]	王安婧, 王亚亚, 梁轩, 闫雅婕, 苏静, 李彩东. 基于PPAR治疗胆汁淤积性肝病的机制与药物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(7): 796-808.
[8]	李青华, 赵艳, 赵海港, 高朋飞, 徐炳欣. ABCB1 G2677T 基因多态性检测在缺血性脑卒中患者应用阿托伐他汀降脂治疗中的价值[J]. 中国临床药理学与治疗学, 2023, 28(6): 633-640.
[9]	王娟, 刘维英, 叶育才, 付文丽, 张莎, 李乐萍. 去甲肾上腺素再摄取抑制剂联合抗毒蕈碱剂治疗阻塞性睡眠呼吸暂停的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(6): 714-720.
[10]	陈满新, 张丙雨, 戴敏. 冠状动脉内靶向应用重组人尿激酶原联合经皮冠状动脉成形术治疗高负荷血栓急性心肌梗死临床疗效[J]. 中国临床药理学与治疗学, 2023, 28(5): 544-549.
[11]	张莉, 蔺兴遥, 尚芸, 王强. 冻伤的病理机制及治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(3): 347-354.
[12]	俞亚红, 宋昱. 左心室辅助装置植入患者的药物治疗[J]. 中国临床药理学与治疗学, 2023, 28(2): 198-204.
[13]	王丹, 鄢晓丽, 张渊. 幽门螺杆菌感染影响胃癌免疫治疗的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 228-234.
[14]	李晨豪, 喻喜华, 闫文浩, 柴宇霞, 李燕燕, 李锟, 李泽运. 儿童癫痫与维生素D相关性研究进展[J]. 中国临床药理学与治疗学, 2023, 28(11): 1299-1306.
[15]	吴莉莉, 梁至, 黄思咏, 王妍. 肾功能亢进对感染性心内膜炎患者万古霉素药动学的影响及有效性与安全性研究[J]. 中国临床药理学与治疗学, 2023, 28(10): 1139-1145.

胃肠间质瘤临床诊治现状与进展

Progress of diagnosis and therapy on gastrointestinal stromal tumors

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价